Wednesday, February 23, 2011
Santarus Inc., of San Diego, and Pharming Group NV, of Leiden, the Netherlands, announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb study evaluating the investigational drug Rhucin (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedema in patients with hereditary angioedema.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.